The Psychiatric Drug Development Landscape Review
Psychiatric drug development remains a critical focus for biopharma, driven by significant unmet patient need, and the complexity of CNS disorders.
This Report Offers Insight Into:
- Targets & Target Crowding: 5-HT2A leads the way for top targets investigated. Uncover the shared involvement of neural circuits and neurotransmitter systems across Psychiatric disorders.
- Delivery Systems & Formulations: Nanoparticles make up 35% of non-viral delivery systems, highlighting efforts to improve brain penetration and pharmacokinetics.
- Clinical Trial Trends: Trial initiations have accelerated since 2023. Discover the psychiatric disease indications and therapies dominating the trial landscape.
- Recent & Upcoming Regulatory Announcements: Including COBENFYTM for schizophrenia, and SPRAVATO® for treatment-resistant depression.
You May Also Be Interested In…
Learn More About Psychiatric
What is Beacon Psychiatric?
- The Most Comprehensive Way to Search the Psychiatric Drug Development Landscape: Unique search ontologies based on Psychiatric drug and trial characteristics
- Market Leading Approach to Psychiatric Preclinical & Clinical Data Curation: Manual curation of key Psychiatric research and development data points by Psychiatric research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Psychiatric company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
